表紙
市場調査レポート

中国の抗真菌剤市場の分析

Research Report on China's Antifungal Drug Market, 2013-2017

発行 China Research and Intelligence 商品コード 258789
出版日 ページ情報 英文 50 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
中国の抗真菌剤市場の分析 Research Report on China's Antifungal Drug Market, 2013-2017
出版日: 2012年12月26日 ページ情報: 英文 50 Pages
概要

近年、中国の抗真菌剤市場は急速に成長しており、2012年には71億人民元(前年比25.2%増)に達しました。今後も年平均(CAGR)20%程度の成長率を維持するものと思われます。

当レポートでは、中国における抗真菌薬市場について分析し、抗真菌剤の特徴や世界市場の構造・傾向、中国市場の基本的構造や現状、主要薬剤別の市場動向(今後5年間の予測値)、現在販売されている薬剤の一覧、今後の市場・技術の発展の方向性などを調査・考察して、その結果を概略以下の内容でお届けいたします。

第1章 抗真菌剤の概要

  • 抗真菌剤の開発経路
  • 抗真菌剤の分類
    • ポリエン
    • ポリペプチドおよびアミノ酸
    • アリルアミン
    • アゾール
    • 金属複合体
    • 植物エキス

第2章 世界の抗真菌剤市場

  • 発症率
  • 市場規模

第3章 中国の抗真菌剤市場の分析

  • 抗真菌剤の市場規模
  • 抗真菌剤の市場シェア
  • 中国の抗真菌剤の市場シェア:主要な種類別
  • 中国の抗真菌剤の市場シェア:メーカー別
  • 抗真菌剤の主な種類の成長率

第4章 中国国内の主な抗真菌剤の分析

  • ボリコナゾール
  • フルコナゾール
  • カスポファンギン
  • イトラコナゾール
  • ミカファンギン
  • テルビナフィン
  • アンホテリシンB
  • エコナゾール
  • ミコナゾール
  • クロトリマゾール
  • ミホナゾール

第5章 中国国内の抗真菌剤市場:製品名と価格

第6章 中国の抗真菌剤市場の発展動向

  • 市場の傾向
  • 技術の傾向

図表一覧

目次

Fungi are usually opportunistic pathogens for healthy human bodies. Under conditions of weakened organism resistance and bad external factors, it is likely to cause general or local fungal infections. In recent years, fungal infection cases tend to gradually increase in China, which is related to following factors to a certain extent:

  • (1) Patients in hospital for a long term caused by severe basic diseases or lots of combined diseases will reduce the immunologic function of organisms to easily cause fungal infection;
  • (2) the misuse of broad-spectrum antibiotics, large usage dosages, long usage periods, excessive varieties, etc. will damage internal microeubiosis and transform formerly-nonpathogenic fungi to dominant bacteria so as to induce fungal infection;
  • (3) the improper application of glucocorticoids inhibits immunity of organisms, damages defense system of organisms and promotes the growth of mildew, which causes iatrogenic fungal infection;
  • (4) patients, such as AIDS patients, with the low immunologic function lose resistance to fungi because of the decline in or losses of their own immunologic functions for many reasons.

Under conditions of weakened organism resistance and bad external factors, conditioned pathogenic fungi for human bodies are possible to cause general or local fungal infection. In addition, with the application of antifungal drugs, drug resistance of fungi increasingly strengthens, so it indicates a sharply rising trend for the clinical application of antifungal drugs.

Fungal infection can be divided into two categories: one is subcutaneous fungal infection, which is called as superficial fungal infection; the other is systemic fungal infection, called as deep fungus infection. Deep fungus infection drugs are always the driving force of the antifungal drug market, with the increasing market share year by year. It accounted for over 90% of the share of China's antifungal drug market in 2011, which was associated with the rising incidence of deep fungus infection and endless emergence of new drugs. As for share of each variety, China's top 5 antifungal drugs in 2011 were separately Voriconazole, Fluconazole, Caspofungin, Itraconazole and Micafungin, amounting to 88.54% of the market share. It is obvious to see the high concentration rate in the market. In recent years, the size of China's antifungal drug market always maintains the rapid increase, which reaches about CNY 7.1 billion in 2012, increasing by around 25.2% YOY.

In recent years, the misuse of broad-spectrum antibiotics, adrenocortical hormones and immunodepressants and the large application of invasive operations cause dysbacteriosis and declining resistance of organisms to fungi, which results in the increasing incidence of deep fungal infection day by day. In addition, fungi and human cells belong to eukaryotic cells. After the long-term administration, it is always considerably toxic for hosts. Meanwhile, drug-resistant strains of fungi for Fluconazole, Itraconazole, Voriconazole and Amphotericin B appear, with the increasing trend. Therefore, the antifungal treatment is extremely troublesome and new-type, powerful and safe antifungal drugs are urgently to be published. Moreover, with the application of antifungal drugs, drug resistance of fungi increasingly enhances, so it indicates a sharply rising trend for the clinical application of antifungal drugs.

It is expected that in coming years, the annual growth rate of market size of China's antifungal drugs will be over 20%. As for manufacturers, there are many opportunities.

More following information can be acquired through this report:

  • Current Market Situations of China's Major Antifungal Drug Varieties
  • Major Enterprises in China's Antifungal Drug Market
  • Development Trend of China's Antifungal Drugs

Following people are recommended to buy this report:

  • Pharmaceutical Enterprises
  • Pharmaceutical Trade Enterprises/Hospitals
  • Investors and Research Institutions Focusing on Antifungal Drug Industry

Table of Contents

1. Overview on Antifungal Drugs

  • 1.1. Development Course of Antifungal Drugs
  • 1.2. Classification of Antifungal Drugs
    • 1.2.1. Polyenes
    • 1.2.2. Polypeptide and Amino Acids
    • 1.2.3. Allylamines
    • 1.2.4. Azoles
    • 1.2.5. Metal Complexes
    • 1.2.6. Plant Extracts

2. Market of Antifungal Drugs Globally

  • 2.1. Incidence
  • 2.2. Market Size

3. Analysis on Antifungal Drug Market in China

  • 3.1. Market Size of Antifungal Drugs
  • 3.2. Market Share of China's Antifungal Drugs
  • 3.3. Market Shares of China's Major Antifungal Drug Varieties
  • 3.4. Market Shares of China's Antifungal Drug Manufacturers
  • 3.5. Growth Rates of Major Antifungal Drug Varieties

4. Analysis on Major Antifungal Drugs in China, 2011-2012

  • 4.1. Voriconazole
  • 4.2. Fluconazole
  • 4.3. Caspofungin
  • 4.4. Itraconazole
  • 4.5. Micafungin
  • 4.6. Terbinafine
  • 4.7. Amphotericin B
  • 4.8. Econazole
  • 4.9. Miconazole
  • 4.10. Clotrimazole
  • 4.11. Bifonazole

5. Product Names and Prices of China's Antifungal Drugs, 2012

6. Development Trend of China's Antifungal Drugs, 2013-2017

  • 6.1. Market Trend
  • 6.2. Technology Trend

Selected Charts

  • Chart Market Size of Global Antifungal Drugs, 2005-2012
  • Chart Market Size of China's Antifungal Drugs, 2007-2012
  • Chart Market Share of Each Sort of China's Antifungal Drugs, 2007-2011
  • Chart Market Shares of Top 20 Antifungal Drug Varieties, 2006-2011
  • Chart Market Shares of Top 20 Antifungal Drug Enterprises in China, 2007-2011
  • Chart Market Shares of China's Voriconazole Manufacturers, 2010-2011
  • Chart Market Size of Voriconazole in China, 2007-2011
  • Chart Market Shares of China's Fluconazole Manufacturers, 2010-2011
  • Chart Market Shares of China's Itraconazole Manufacturers, 2010-2011
  • Chart Market Shares of China's Terbinafine Manufacturers, 2010-2011
  • Chart Product Names and Reference Prices of China's Major Antifungal Drugs
  • Chart Prediction on Market Size of China's Antifungal Drugs, 2013-2017
Back to Top